TOP HEADLINES

Featured Story

Can Gilead break into cancer? With Zydelig approval, it gets its chance

Armed with a brand-new FDA approval for its blood cancer drug Zydelig (idelalisib), Gilead will take on the oncology market.

Eli Lilly's Q2 profit sags on patent expirations but beats (low) expectations

Eli Lilly said 2014 would be an extraordinarily challenging year, and judging from its second-quarter earnings, that prediction wasn't wrong. Lilly's revenue dropped 17% to $4.9 billion in the second quarter, largely because the company lost its patent protection on two of its biggest blockbusters: the anti-depressant Cymbalta, which once brought in nearly $5 billion in sales annually, and osteoporosis drug Evista, previously a $1-billion-a-year hit.

Payer pushback aside, Sovaldi, and so Gilead, has another huge quarter

Gilead Sciences' juggernaut, Sovaldi, keeps on rolling along despite the pushback from payers, politicians and health officials over the high price of the hepatitis C cure. It racked up another $3.5 billion sales in the second quarter, on top of the nearly $2.3 billion in the first, a sum that made it the fastest drug launch ever.

$9.9M 'golden hello' awaits Shire chief Ornskov at new AbbVie post

When AbbVie buys out Shire for nearly $55 billion in a deal the two companies agreed on last week, there will be no golden parachute awaiting Shire chief Flemming Ornskov. Instead, there's a signing bonus in order: The helmsman will pocket just under $10 million for staying on with the combined company in a new role.

Pfizer looks to boost Harmonet contraceptive in Asia via loverly brand site

If someone asked who you'd turn to for relationship advice, chances are you wouldn't say Pfizer. But that could change.

MORE NEWS

From Our Sister Sites

FierceVaccines

According to the SEC, vaccine company CytoGenix was foundering financially when two men hatched a plan to convince investors otherwise. And now, the pair is facing charges.

FiercePharma Manufacturing

Most companies voluntarily recall products, and sometimes even stop production, when they or the FDA find quality issues. In the case of a Texas compounder, the FDA has formally requested that it halt sterile drug work and pull back all of its sterile products.